AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2038242
Drug: Therapist-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-based cognitive behavioral therapy
Trial: 24183563
Drug: Pimavanserin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin 40 mg per day
Trial: 9564797
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg total daily dose
Trial: 9564797
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg total daily dose
Trial: 9564797
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 microg total daily dose
Trial: 9564797
Drug: Budesonide 1600
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 1600 microg total daily dose
Trial: 2500670
Drug: Enprostil 35-140
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 35-140 mcg (acute)
Trial: 2500670
Drug: Enprostil 35
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 35 mcg or 70 mcg BID (chronic)
Trial: 22784037
Drug: Once-daily tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tenofovir (TDF)
Trial: 22784037
Drug: Combination tenofovir‐emtricitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tenofovir‐emtricitabine (TDF‐FTC)
Trial: 12678539
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate ointment (0.2% twice daily) applied to the perianal area
Trial: 12678539
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied to the perianal area
Trial: 3191944
Drug: Sertraline 25
RxNorm normalized name: sertraline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 25 mg
Trial: 3191944
Drug: Sertraline 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 75 mg
Trial: 25457977
Drug: Chiropractic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic manipulative therapy (MT) plus rehabilitation
Trial: 23237514
Drug: Anti-stretch mark
RxNorm normalized name: Mederma Stretch Mark Therapy
DrugBank: Glycyrrhizic acid (DB13751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-stretch mark cream containing hydroxyprolisilane-C, rosehip oil, Centella asiatica triterpenes and vitamin E
Trial: 23237514
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cream without active ingredients)
Trial: 21529979
Drug: Routine Glutamic
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Routine Glutamic Acid Decarboxylase Antibody (GADA) testing
Trial: 16823248
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 mg/day for the first 2 days, then 25 mg/day for 90 days)
Trial: 16823248
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg/day for 90 days)
Trial: 16823248
Drug: Doxazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2 mg/day for 90 days)
Trial: 10799347
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg valerian and 120 mg hops (low dosage)
Trial: 10799347
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg valerian and 360 mg hops (high dosage)
Trial: 9404921
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (busulfan 16 mg/kg, etoposide 40 mg/kg, cytosine arabinoside 3 g/m2 x 4) followed by autologous peripheral blood stem cell transplantation (ABSCT) in 13 patients.
Trial: 9404921
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered concurrently with the BEA regimen during conditioning in 47 patients.
Trial: 8362632
Drug: Erythromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1000 mg/day for 10 days) in Group A
Trial: 8362632
Drug: Roxithromycin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (300 mg/day for 10 days) in Group B
Trial: 8362632
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g/day for 14 days) in Group C
Trial: 3750135
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine 1.5 mg/kg 4‐6‐hourly as required
Trial: 20229000
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg kg(‐1) (small-dose group, n = 12)
Trial: 20229000
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg kg(‐1) (large-dose group, n = 12)
Trial: 20229000
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of midazolam (0.2 and 0.3 mg kg(‐1))
Trial: 18520802
Drug: PPX/carboplatin (PPX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPX/carboplatin (PPX 210 mg/m/10 min without routine steroid premedication)
Trial: 18520802
Drug: Paclitaxel/carboplatin (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/carboplatin (Paclitaxel 225 mg/m/3 h with standard premedication)
Trial: 3526617
Drug: Corinfar administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corinfar administered sublingually at a dose of 10-30 mg
Trial: 31262371
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g n‐3 PUFA daily for 3 months
Trial: 31262371
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g n‐3 PUFA daily for 3 months (after washout)
Trial: 15372589
Drug: entacapone 200
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entacapone 200 mg
Trial: 15372589
Drug: entacapone 400
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: entacapone 400 mg
Trial: 15372589
Drug: entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entacapone (200 mg and 400 mg)
Trial: 11203847
Drug: Core build-ups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core build-ups (all materials) after crown preparation
Trial: 11203847
Drug: Amalgam core
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amalgam core build-ups after crown preparation
Trial: 3510594
Drug: Cold potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold potassium cardioplegia with St. Thomas' Hospital solution (Group 1)
Trial: 31006007
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (EPA and DHA) at doses reflecting 1, 2, or 4 portions of oily fish per week (3.27 g EPA + DHA per portion)
Trial: 28671082
Drug: Zhuang medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuang medicine medicated thread moxibustion
Trial: 24012033
Drug: Intravenous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoxaparin
Trial: 21127284
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg levobupivacaine + 10 μg fentanyl
Trial: 21127284
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg levobupivacaine + 10 μg fentanyl
Trial: 21127284
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg levobupivacaine + 10 μg fentanyl
Trial: 16820547
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily, n = 344)
Trial: 16820547
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 mg twice daily, n = 342)
Trial: 10886201
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravenous vitamin K
Trial: 10886201
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravenous vitamin K
Trial: 10886201
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous vitamin K
Trial: 9039339
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen replacement therapy (17 beta-oestradiol 2 mg daily on days 1-22 and 1 mg daily on days 23-28, norethisterone 1 mg days 13-22)
Trial: 9039339
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen replacement therapy (oestradiol 50 micrograms/24 h on days 1-28, norethisterone 250 micrograms/24 h on days 15-28)
Trial: 1554119
Drug: Transdermal 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 10% lidocaine gel with 3% glycyrrhetinic acid monohemiphthalate disodium (GAMHPh)
Trial: 1554119
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Transdermal 10% lidocaine gel without GAMHPh)
Trial: 27246516
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation programme combining multimodal exercises with psychologist‐lead cognitive‐behavioural therapy sessions
Trial: 25676529
Drug: Rivaroxaban (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (with prestudy heparin)
Trial: 25676529
Drug: Enoxaparin/VKA (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/VKA (with prestudy heparin)
Trial: 25676529
Drug: Rivaroxaban (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (without prestudy heparin)
Trial: 25676529
Drug: Enoxaparin/VKA (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/VKA (without prestudy heparin)
Trial: 17999429
Drug: BTX‐B (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐B (20 U, 100 U, or 500 U/0.2 mL)
Trial: 16206608
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (i.v. prospidin 200‐300 mg/week + i.m. methotrexate 10 mg/week)
Trial: 16206608
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy (10 mg/week i.m.)
Trial: 7477994
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral prednisone (20 mg daily for the first week and 10 mg daily for the second week)
Trial: 2142574
Drug: Single-dose ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ethinyl estradiol from Femovan
Trial: 2142574
Drug: Single-dose ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ethinyl estradiol from Marvelon
Trial: 19678952
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg human AAT (Prolastin) weekly infusions
Trial: 17367973
Drug: Injection protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection protocol used in this study
Trial: 15311314
Drug: SRP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP and 250 mg of metronidazole (3 times a day for 10 days)
Trial: 9765722
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation therapy (lumpectomy with axillary dissection)
Trial: 3035002
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg i.v.)
Trial: 24006670
Drug: Transcutaneous acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous acupoint electrical stimulation (TAES) combined with target controlled infusion of Propofol
Trial: 24006670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (target controlled infusion of Propofol without TAES)
Trial: 17029347
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (hemodynamic maneuvers, magnesium, statins, endothelin antagonists, steroid drugs, anticoagulant/antiplatelet agents, intrathecal fibrinolytic drugs)
Trial: 17029347
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel antagonists (nicardipine)
Trial: 17029347
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy (balloon angioplasty, intraarterial vasodilating agents)
Trial: 27253231
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of 20 mg nafamostat mesilate
Trial: 27253231
Drug: 6-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-hour infusion of 20 mg nafamostat mesilate
Trial: 27253231
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (6-hour infusion)
Trial: 21847539
Drug: Topical amitriptyline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical amitriptyline, ketamine, and lidocaine (AKL) applied three times a day until 2 weeks post-radiotherapy.
Trial: 8771420
Drug: Early endoscopy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early endoscopy combined with endoscopic therapy for patients with bloody aspirate
Trial: 1466212
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (1 mg.kg‐1)
Trial: 25295434
Drug: Specialized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized treatment (CAU + PEP + psychiatric consultation or cognitive‐behavioral therapy)
Trial: 25295434
Drug: Primary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary treatment (CAU or CAU + PEP)
Trial: 21742445
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment + naltrexone
Trial: 20675864
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy laser therapy (Group A, n=35)
Trial: 20675864
Drug: Vacuum therapy
RxNorm normalized name: Rapport Vacuum Therapy Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum therapy combined with Ultra Reiz current (Group C, n=32)
Trial: 20675864
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (Group B, n=27)
Trial: 15749735
Drug: Magnesium (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (80 mg kg(‐1) followed by infusion at 2 g h(‐1))
Trial: 12884643
Drug: Statins (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (specific type not mentioned, but atorvastatin is referenced for cost comparison)
Trial: 8876359
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine pranobex (1 g orally 3 times a day for 6 weeks)
Trial: 6696302
Drug: Oxacillin 500
RxNorm normalized name: oxacillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxacillin 500 mg qid for five days
Trial: 31314106
Drug: Inhalation Injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Injury (INHI)
Trial: 31314106
Drug: No Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Inhalation Injury (No INHI)
Trial: 28699267
Drug: Lucerastat 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucerastat 1,000 mg b.i.d. for 12 weeks
Trial: 28699267
Drug: Enzyme Replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme Replacement Therapy (ERT) only
Trial: 26758265
Drug: Arthroscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic surgery (arthroscopic debridement and partial resection of degenerative knee tissues) in addition to optimised non-operative therapy
Trial: 26758265
Drug: Optimised non-operative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised non-operative therapy only
Trial: 24022643
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.5 % solution
Trial: 24022643
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide 250 mg/day
Trial: 24022643
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no agent)
Trial: 20669670
Drug: Ginaton 1
RxNorm normalized name: Genaton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginaton 1 mg/kg
Trial: 17505565
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (PPI, clarithromycin, amoxicillin)
Trial: 17505565
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (PPI, clarithromycin, metronidazole)
Trial: 17505565
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (PPI, amoxicillin, metronidazole)
Trial: 17505565
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (PPI, bismuth, metronidazole, tetracycline) for 7-10 days
Trial: 15017231
Drug: Intraplaque electromotive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraplaque electromotive administration of 5 mg verapamil and 8 mg dexamethasone
Trial: 15017231
Drug: Electromotive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electromotive administration of 2% lidocaine
Trial: 9241405
Drug: High phenylalanine
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High phenylalanine supplement over 3 months
Trial: 3329102
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg/day before breakfast for six months
Trial: 3329102
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/day before breakfast for six months
Trial: 3329102
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg/day before breakfast from 7th to 12th month
Trial: 21539403
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of lisdexamfetamine dimesylate 50 mg
Trial: 21539403
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of lisdexamfetamine dimesylate 50 mg
Trial: 8566979
Drug: 0.15% cream
RxNorm normalized name: ROFLUMILAST 0.15% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% cream
Trial: 8566979
Drug: 0.3% cream
RxNorm normalized name: ROFLUMILAST 0.3% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% cream
Trial: 8566979
Drug: 0.5% solution
RxNorm normalized name: VueBlu 0.5% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% solution
Trial: 2528439
Drug: Benzoyl peroxide/potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream with hydrocortisone
Trial: 2528439
Drug: Benzoyl peroxide/potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream without hydrocortisone
Trial: 2528439
Drug: Aqueous astringent
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous astringent cream base alone
Trial: 2528439
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide alcoholic gel